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Abstract
Background: Factors associated with serologic hepatitis B virus (HBV) outcomes in HIV-infected individuals remain
incompletely understood, yet such knowledge may lead to improvements in the prevention and treatment of chronic HBV
infection.
Methods and Findings: HBV-HIV co-infected cohort participants were retrospectively analyzed. HBV serologic outcomes
were classified as chronic, resolved, and isolated-HBcAb. Chronic HBV (CHBV) was defined as the presence of HBsAg on two
or more occasions at least six months apart. Risk factors for HBV serologic outcome were assessed using logistic regression.
Of 2037 participants with HBV infection, 281 (14%) had CHBV. Overall the proportions of HBV infections classified as CHBV
were 11%, 16%, and 19% for CD4 cell count strata of $500, 200–499, and ,200, respectively (p,0.0001). Risk of CHBV was
increased for those with HBV infection occurring after HIV diagnosis (OR 2.62; 95% CI 1.78–3.85). This included the subset
with CD4 count $500 cells/mL where 21% of those with HBV after HIV diagnosis had CHBV compared with 9% for all other
cases of HBV infection in this stratum (p=0.0004). Prior receipt of HAART was associated with improved HBV serologic
outcome overall (p=0.012), and specifically among those with HBV after HIV (p=0.002). In those with HBV after HIV, HAART
was associated with reduced risk of CHBV overall (OR 0.18; 95% CI 0.04–0.79); including reduced risk in the subsets with CD4
$350 cells/mL( p,0.001) and CD4 $500 cells/mL( p=0.01) where no cases of CHBV were seen in those with a recent history
of HAART use.
Conclusions: Clinical indicators of immunologic status in HIV-infected individuals, such as CD4 cell count, are associated
with HBV serologic outcome. These data suggest that immunologic preservation through the increased use of HAART to
improve functional anti-HBV immunity, whether by improved access to care or earlier initiation of therapy, would likely
improve HBV infection outcomes in HIV-infected individuals.
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Introduction
Liver-related complications have become an increasingly
important cause of morbidity and mortality in HIV-infected
patients since the advent of highly active antiretroviral therapy
(HAART).[1,2,3,4,5,6] Despite the high prevalence of HBV co-
infection among individuals with HIV and its impact on
management and clinical outcomes, the optimal strategies for
the prevention and treatment of chronic HBV infection (CHBV)
in those with HIV are not well defined.
HBV vaccination of susceptible individuals is recommended as a
means of primary prevention,[7] but the clinical effectivenessof HBV
vaccine in this population when given after HIV diagnosis may be
limited,[8] and as many as 20% of HBV infections in HIV-infected
individuals may be chronic.[9,10] In a small study of HBV/HIV co-
infected individuals from the pre-HAART era, the mean CD4 cell
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the 24 subjects that cleared HBsAg.[9] Thus, in the absence of an
effective vaccine for primary prevention, preservation of higher CD4
cellcounts and anti-HBV immunity during the course of HIV may be
associated with reduced risk of becoming chronically infected with
HBV. Therefore, either improved access to or earlier initiation of
HAART may provide an effective method for prevention of HBV
associated disease in this patient population.
In addition to informing possible prevention practices for HBV,
an evaluation of clinical associations with HBV serologic outcomes
may help indirectly inform treatment strategies for HBV in patients
with HBV/HIV co-infection. Current HIV-treatment guidelines
recommend initiation of HAART for HBV/HIV co-infected adults
when HBV treatment is indicated [11,12] although supporting data
are very limited. Some have hypothesized that HAART may
improve rates of response to anti-HBV therapy.[13] Supporting this
hypothesis, improvement of anti-HBV immunity with ritonavir
monotherapy[14], and seroconversion from HBsAg to HBsAb
followinginitiationofHAARThavebeenreported.[15]Inaddition,
previous investigations have found associations between CD4
responses to HAART with HBV viral suppression[16] and possibly
HBV seroconversion.[17] However, the conclusions from these
studies regarding the impact of HAART upon improvement of
HBV serologic markers were limited because few individuals
cleared HBsAg and most were receiving HAART. Because of these
limitations, better understanding of the determinants of HBV
serologic outcome may suggest possible improvements in the care of
those with chronic HBV/HIV co-infection, such as the addition of
HAART to anti-HBV therapy.
Therefore, to inform future HBV prevention and treatment
strategies we sought to evaluate the associations between the risk of
CHBV and the timing of HBV infection relative to HIV diagnosis
(before or after), CD4 cell count at the time of HBV diagnosis, and
HAART use preceding HBV diagnosis. We hypothesized that
such factors, reflective of anti-HBV immunity at the time of HBV
infection or diagnosis, would be associated with the subsequent




The U.S. Military HIV Natural History Study (NHS) is an
ongoing, continuous enrollment observational cohort of HIV-
infected Department of Defense (DoD) beneficiaries followed at
sevenparticipatingmilitarymedicalcentersintheUnitedStatesand
has been previously described.[8] Enrolling since 1986, the NHS
has approximately 5000 participants with signed, written consent.
Patients are seen every six months following enrollment. Data
collected at each visit include demographic information, past and
interim medical history, medications, vaccinations, and standard
clinical laboratory studies. HIV exposure category is not routinely
captured, however rates of HIV risk behaviors have been previously
reported and intravenous drug use is rare (,1%).[18]
Ethics Statement
All adult DoD beneficiaries with a diagnosis of HIV infection
followed at a participating site and able to provide consent were
eligible for participation in the NHS. Approval for this research was
obtained from the institutional review boardat eachparticipating site.
Participant Selection and Definitions
All NHS participants with a documented date of HIV
seropositivity through 2008, and serologic diagnosis of HBV
infection as defined below were included in the current analyses.
HBV infection and serologic outcomes were defined using the
following non-overlapping categories:
1. Chronic HBV infection (CHBV), defined as ever having
reactive HBsAg on two or more separate occasions at least six
months apart,
2. Isolated HBcAb (IcHBV), defined as having reactive HBcAb
on two or more separate occasions, and tested for both HBsAg
and HBsAb and never positive for HBsAg nor HBsAb, or
3. Resolved HBV infection (RHBV), defined as having reactive
HBcAb and HBsAb, and never meeting criteria for CHBV.
All cases of HBV infection were also sub-classified into one of
two groups a priori based upon the timing of HBV diagnosis
relative to HIV diagnosis. Participants initially non-reactive for
both HBsAg and HBcAb on or after the date of HIV infection but
later meeting criteria for HBV infection were classified as having
HBV infection definitively after HIV diagnosis; those with HBV
diagnosis at the time of HIV diagnosis and those testing positive
for HBV after HIV but missing previous negative HBsAg or
HBcAb results (i.e. unknown timing of HBV infection relative to
HIV diagnosis) were grouped together as HBV infections which
did not definitively occur after HIV.
Mono/dual antiretroviral therapy (ART) and highly active
antiretroviral therapy (HAART) use was categorized based on use
within the 12 months preceding HBV diagnosis. HAART was
defined as a combination of at least three antiretroviral agents,
similar to previous investigations.[19] HBV-active mono/dual
ART or HAART was defined as ART or HAART containing
lamivudine, emtricitibine, or tenofovir. The presence of an AIDS-
defining illness was defined using 1993 CDC criteria,[20] with the
exception of isolated CD4 count ,200 cells/mL. Infection with
syphilis, N. gonorrhea, C. trachomatis, or genital herpes simplex virus
was considered to be a sexually transmitted infection (STI).
Study Design and Statistical Methods
Descriptive statistics were used to examine the characteristics of
participants with HBV infection overall and by HBV outcome
category. Medians were reported with inter-quartile ranges (IQR).
Proportions were compared with chi-square or Fisher’s Exact tests
as appropriate. Continuous variables were compared using the
Kruskal-Wallis test. Univariate and multivariate logistic regression
models were used to assess factors associatedwithIcHBV compared
with RHBV, and CHBV compared with RHBV. Subset analyses
evaluating factors associated with CHBV in those with HBV
infection definitively after HIV diagnosis were also performed. For
analyses regarding use of HAART in individuals with HBV
definitively after HIV, participants were sub-grouped by non-
exclusive CD4 categories of $350 and $500 cells/mL. Initial
multivariate models included variables captured for at least 75% of
participants with p#0.10 in univariate analysis. Final multivariate
models incorporated adjustments for factors which were different
between HBV diagnoses before 1996 and HBV diagnoses in 1996
or later. To further explore the interactions between CD4 cell
count, timing of HBV diagnosis relative to HIV diagnosis, and
HAART use, we classified subjects into mutually exclusive clinically
relevant categories based on their CD4 count at the time of HBV
diagnosis (,200, 200–499, or $500 cells/mL). Differences in the
proportion of participants with CHBV and RHBV across CD4
categories were examined using the Cochran-Armitage test for
trend. Odds ratios (OR) were reported with 95% confidence
intervals (CI). All p-values were two-sided, and all statistical analyses
were performed using SAS software (version 9.1, Cary, NC).
HBV Serologic Outcomes in HIV
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A total of 2,037 participants met criteria for HBV infection, and
were included overall. (Table 1) The median number of HBV
serologic panel assessments was 7 (IQR 4-11) overall; 8 (IQR 5-12)
for those with CHBV, 5 (IQR, 3–8) for those with IcHBV, and 7
(3–11) for those with RHBV. Of those classified as having CHBV,
255 (91%) were persistently reactive for HBsAg beginning at the
time of HBV diagnosis and 26 (9%) were reactive for HBV
serologic markers other than HBsAg at the time of HBV diagnosis
and later became persistently reactive for HBsAg. Of those
classified as having RHBV, 1233 (79%) were reactive concurrently
for HBcAb and HBsAb at the time of HBV diagnosis and never
became chronically infected, and 330 (21%) had initial serologic
evidence of HBV infection without HBsAb, never became
chronically infected, and later developed HBsAb. A total of 407
(20%) HBV infections were diagnosed after 1995. Differences in
characteristics at the time of HBV diagnosis between those with
HBV diagnosed during the pre-HAART era compared with the
HAART era included age (p,0.01), gender (p=0.03), known HIV
seroconversion status (p,0.01), and ethnicity (p=0.06), whereas
median CD4 cell count at HBV diagnosis was similar for the pre-
HAART and HAART eras (474 vs. 443, respectively; p=0.20).
Seventy-nine percent of participants had not received any HIV
therapy in the year prior to HBV diagnosis. Two percent of the
participants who received only ART (7/339) and 91% of those
who received HAART (79/87) received HBV-active agents as a
component of therapy. Interferon therapy was rare in all HBV
serologic outcome categories. Five (1.8%) of those who developed
CHBV, 3 (1.6%) of those who developed IcHBV, and 30 (1.9%) of
those who developed RHBV received interferon treatment
following HBV diagnosis.
Factors Associated with IcHBV and CHBV Overall
Results of univariate and multivariate analyses of factors
associated with IcHBV or CHBV compared with RHBV are
provided separately (Text S1).
Table 1. Characteristics of participants at the time of HBV diagnosis by HBV infection outcome.
Characteristic N CHBV (N=281) IcHBV (N=193) RHBV (N=1563)
HIV Seroconverter, N (%) 2037 132 (47) 67 (35) 838 (54)
Age, years, median (IQR) 2037 31 (27–35) 34 (28–37) 32 (27–37)
Years from HIV to HBV diagnosis, median (IQR) 2037 1.2 (0.1–3.5) 1.4 (0.1–4.0) 0.9 (0.1–3.2)
Male, N (%) 2037 275 (98) 183 (95) 1524 (98)
Self-identified ethnicity, N (%)
Caucasian 885 112 (40) 72 (37) 701 (45)
African American 950 147 (52) 104 (54) 699 (45)
Hispanic/Puerto Rican/Mexican 153 18 (6) 11 (6) 124 (8)
Other 49 4 (1) 6 (3) 39 (3)
CD4 cell count, cells/mL, median (IQR) 1979 413 (272–578) 434 (293–629) 485 (320–664)
HIV RNA, log10copies/mL, median (IQR) 571 4.3 (3.9–4.7) 4.2 (3.6–4.9) 4.2 (3.4–4.7)
AIDS-Defining Illness, N (%) 2037 16 (6) 13 (7) 81 (5)
Anti-HCV prior to HBV, N (%) 230 4 (9) 2 (15) 11 (7)
STI prior to HBV, N (%) 2021 141 (51) 104 (55) 796 (51)
ART use prior to HBV
a, N (%)
None 1604 211 (75) 149 (77) 1244 (80)
HBV inactive mono/dual ART 339 62 (22) 40 (21) 237 (15)
HBV active mono/dual ART 7 2 (1) 1 (1) 4 (1)
HBV inactive HAART 8 1 (1) 0 (0) 7 (1)
HBV active HAART 79 5 (2) 3 (2) 71 (5)
HBV vaccination doses, N (%)
None 1783 247 (88) 171 (89) 1365 (87)
1–2 145 23 (8) 12 (6) 110 (7)
$3 109 11 (4) 10 (5) 88 (6)
HBV vaccination relative to HIV, N (%)
None 1783 247 (88) 171 (89) 1365 (87)
All doses prior to HIV 82 6 (2) 4 (2) 72 (5)
Doses before and after HIV 32 2 (1) 3 (2) 27 (2)
All doses after HIV 140 26 (9) 15 (8) 99 (6)
HBV after HIV, N (%) 2037 60 (21) 22 (11) 169 (11)
aWithin the year prior to HBV diagnosis.
CHBV, chronic hepatitis B virus infection; IcHBV, Isolated HBcAb hepatitis B virus infection; RHBV, resolved hepatitis B virus infection; HBV, hepatitis B virus; HCV, hepatitis
C virus; HIV, human immunodeficiency virus; ART, antiretroviral therapy; HAART, highly active antiretroviral therapy; STI, sexually transmitted infection.
doi:10.1371/journal.pone.0008687.t001
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Categories
Those with HBV diagnosis when the CD4 count was $500 had
significantly different serologic outcomes than those with HBV
diagnosis when CD4 counts were either 200–499 (p=0.003) or
,200 (p=0.0001) (Fig. 1). Furthermore, the proportion of
participants with CHBV increased as the CD4 cell count at
HBV diagnosis decreased (11%, 16%, and 19% for CD4 cell
count strata of $500, 200–499, and ,200, respectively;
p,0.0001), whereas the proportion of participants with RHBV
increased as CD4 cell count at the time of HBV infection
increased (68%, 75%, and 81% for CD4 cell count strata of ,200,
200–499, and $500, respectively; p,0.0001).
HBV Infection Serologic Outcome by Onset of HBV
Infection Relative to HIV Diagnosis
For those with HBV after HIV, 24% of infections were CHBV
compared with 12% for all other HBV infections (i.e. thosediagnosed
concurrently with HBV and HIV, and those with unknown timing of
HBV infection relative to HIV) (p,0.0001) (Fig. 2A). Furthermore,
those with HBV infection following HIV diagnosis had different
HBV serologic outcomes by CD4 category compared with those who
were HBV infected but not definitively infected with HBV after HIV
(Fig. 2B). Even in the subgroup with CD4 count $500 at the time of
HBV diagnosis, those with HBV after HIV were more likely to have
CHBV (21% compared with 9%, p=0.0004).
HBV Infection Serologic Outcome and Receipt of
Antiretroviral Therapy
Individuals who received HAART in the year prior to HBV
diagnosis had significantly different serologic outcomes than those
who did not receive HAART prior to HBV diagnosis (p=0.012;
Fig. 3A). Regarding HBV active therapy, the proportion of
participants with CHBV was not significantly lower for those
receiving HBV-active ART (29%) compared with those on HBV-
inactive ART (18%; p=0.62) although only seven participants
were in the former category. Additionally, proportions of CHBV
were similar for those on HAART either with or without HBV-
active agents (6% vs. 13%, respectively; p=0.45), although only
eight participants received HBV-inactive HAART.
In evaluating HBV serologic outcomes by HAART receipt
using CD4 cell count strata of ,200, 200–499, and $500 cells/
mL, outcomes were improved in those receiving HAART but
Figure 1. HBV infection outcome by CD4 cell count strata.
(CHBV, chronic hepatitis B virus infection; IcHBV, Isolated HBcAb
hepatitis B virus infection; RHBV, resolved hepatitis B virus infection).
doi:10.1371/journal.pone.0008687.g001
Figure 2. HBV infection outcome by timing of HBV infection relative to HIV diagnosis. (Panel A, Overall; Panel B, by CD4 cell count strata)
(CHBV, chronic hepatitis B virus infection; IcHBV, Isolated HBcAb hepatitis B virus infection; RHBV, resolved hepatitis B virus infection).
doi:10.1371/journal.pone.0008687.g002
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stratum. (Fig. 3B) In addition, for the subset of those with CD4 cell
count $350 cells/mL at HBV diagnosis, 2/61 (3%) who received
HAART developed CHBV compared with 171/1309 (13%) who
did not receive HAART (p=0.02).
Finally, the association between improved HBV outcomes and
receipt of HAART was strongest for participants with HBV infection
after HIV diagnosis (Fig. 3C). For individuals with HBV infection
after HIV diagnosis, 2/37 (5%) receiving HAART prior to HBV
diagnosis developed CHBV compared with 58/214 (27%) for those
not receiving HAART (p=0.003). Among those with HBV after
HIV, receipt of HAART was associated with an 82% reduction in
risk of developing CHBV (adjusted OR 0.18; 95% CI 0.04–0.79).
Lastly, for those with HBV after HIV and with CD4 count $350,
none of those on HAART developed CHBV compared with 39
(28%) of those not on HAART (p,0.001); similarly, among those
with CD4 count $500, none of those on HAART developed CHBV
compared with 21 (26%) of those not on HAART (p=0.01).
Discussion
Our investigation regarding factors associated with HBV
serologic outcome in HIV-infected adults both confirms and
expands upon previous findings. While the majority of all HBV
infections in our study were resolved, over one quarter of HBV/
HIV co-infected participants had some form of unresolved
infection. Furthermore, approximately 20% of HBV infections
occurring after HIV diagnosis were chronic regardless of CD4 cell
count at the time of HBV diagnosis. These observations emphasize
the importance of HBV prevention for all patients with HIV,
including those with high CD4 cell counts. Our findings also
highlight the association between functional immune status at the
time of HBV infection and subsequent HBV serologic outcome,
and suggest that improved functional anti-HBV immunity through
maintenance of higher CD4 cell counts and increased use of
HAART would likely improve serologic HBV outcomes in HIV-
infected individuals.
From a simplified perspective the immune response to HBV
infection occurs in two phases: phase one, the response to acute
HBV exposure, and phase two, the response required to maintain
immunologic control of HBV within hepatocytes indefinitely. In
both phases strong, polyclonal, multi-specific CD8 T cells appear
to be the primary component, although CD4 T cells serve a
critical role in supporting such responses.[21,22,23] Therefore,
interventions to improve HBV serologic outcomes may target one
or both phases of this response. The importance of cellular
Figure 3. HBV infection outcome by ART use prior to HBV diagnosis. (Panel A, Overall; Panel B, by CD4 cell count strata; Panel C, by timing of
HBV infection relative to HIV diagnosis). (CHBV, chronic hepatitis B virus infection; IcHBV, Isolated HBcAb hepatitis B virus infection; RHBV, resolved
hepatitis B virus infection).
doi:10.1371/journal.pone.0008687.g003
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infection is supported by several observations from our study
including an increased risk of CHBV in those with HBV infection
after HIV diagnosis and those with lower CD4 cell counts at the
time of HBV diagnosis, as well as an increased likelihood of
RHBV in those with higher CD4 cell counts, and improvements in
HBV outcome for those infected with HBV while receiving
HAART. The central importance of cellular immune function in
determining HBV serologic status is also supported by a smaller
previous study which similarly found those with CHBV had lower
mean CD4 cell counts, and the proportion of CHBV infections in
those with HBV after HIV was high, approximately 20%.[9]
Our findings also demonstrate the complex relationship
between HBV serologic outcomes and the degree of immunologic
function during either phase of the immune response to HBV.
While CD4 cell count at the time of HBV diagnosis was inversely
related to the risk of CHBV, such risk was also altered by whether
or not HBV infection occurred after HIV diagnosis. In other
words, an individual infected with HBV prior to HIV whose CD4
count later declined had lower risk of CHBV than an individual
infected with HBV after HIV diagnosis with a similar CD4 cell
count. Therefore, our study suggests a significant portion of HBV
serologic outcome is determined by an individual’s ability to
mount an effective immune response at the time of HBV exposure,
regardless of future alterations in immune status. HBV serologies
have been reported to fluctuate over time in HIV-infected
individuals which could potentially limit conclusions from our
study in this regard.[24,25] However, even though we did not
specifically evaluate longitudinal changes in HBV serologies, 91%
of individuals we classified as having CHBV were persistently
reactive for HBsAg from the date of HBV diagnosis further
suggesting that CHBV is established early in the course of HBV
infection. This observation also supports our design evaluating the
associations between factors known at the time of HBV diagnosis
with subsequent HBV serologic outcome. Additionally, true HBV
reverse seroconversion in HIV-infected individuals is reportedly
very rare.[26] Therefore, we conclude that immunologic events
during phase one of the response to HBV infection are the crucial
determinants of HBV serologic outcome. Considering our results
together with previous studies reporting low rates of HBsAg
clearance over time in those with HBV/HIV co-infec-
tion,[16,17,27,28,29] those infected with CHBV after HIV
infection may have reduced ability to ever develop adequate
immunity to control HBV, or develop resolved HBV infection.
The high proportion of CHBV in those with HIV, including
those with CD4 cell count $500, combined with the observation
that long-term HBV serologic outcome may be determined at the
time of HBV exposure, further emphasizes the importance of
HBV prevention in this patient population. Notably, those with
HBV infection after HIV diagnosis who received HAART
immediately preceding HBV diagnosis were less likely to have
CHBV than those not receiving HAART. For such individuals on
HAART the proportion of those with CHBV was 5%, similar to
HIV-negative individuals infected with HBV as adults.[10] This
observation suggests HAART is capable of reversing the HIV-
associated dysfunction of anti-HBV CD8 and CD4 T cells
required for a successful response to acute HBV exposure.
Furthermore, the ability of HAART use to alter HBV outcome
remained evident in the subset of participants with CD4 cell count
$500. Not surprisingly, HAART appeared to have little or no
benefit for those who were likely infected with HBV before HIV
diagnosis.
As the second phase of the immune response to HBV infection
involves similar CD8 and CD4 T cell responses to those seen after
acute HBV exposure[21] and because a significant portion of our
participants developed RHBV (a potential goal of CHBV
treatment), our findings may also have relevance regarding the
treatment of CHBV in individuals with HIV. As a cross-sectional
study evaluating HBV serologies and not clinical outcomes, our
analysis was not designed to evaluate the optimal treatment of
CHBV. However, two previous cohort investigations suggested
that HAART may improve HBV-related treatment outcomes
including HBV viral suppression and seroconversion.[16,17] In
addition, small studies of HBV/HIV co-infected individuals have
demonstrated reconstitution of anti-HBV CD8 and CD4 T cell
responses following HAART initiation in those with
RHBV,[30,31] further supporting the concept that HAART
may improve the second phase of the immune response to HBV,
thereby increasing HBV treatment success. Our study provides
indirect support of current HIV treatment guideline recommen-
dations,[11,12] suggesting the use of HAART may improve
serologic responses to HBV treatment indirectly through improve-
ments in anti-HBV immunity, including the subset of patients with
high CD4 cell counts. Previous studies have also shown low rates
of HBeAg or HBsAg seroconversion with HBV mono- or dual
therapy in HIV-infected individuals.[32,33,34] Therefore, the
optimal treatment approach for HBV infection in HIV-infected
individuals may indeed be anti-HBV therapy as a component of
HAART.
The optimal strategies for prevention and treatment of HBV in
HIV-infected individuals remain to be defined. From our
investigation, HBV serologic outcomes were significantly related
to several factors reflecting the functional immune status of an
individual. Future investigations will need to evaluate such
associations with clinical outcomes. Evidence and support for the
earlier initiation of and improved access to HAART continue to
increase,[32,33] and an additional benefit associated with
HAART administration in those with both low and high CD4
cell counts may be reduced risk of CHBV. This reduced risk may
result from improved function of the factors necessary for a
successful immune response to HBV, in addition to direct anti-
HBV effects. Therefore, increased use of the currently recom-
mended first-line HAART regimens may significantly reduce the
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